

Anti-VCAM-1 Antibody (5T238)

Product Details

Ig Type:	Rabbit IgG
Reactivity:	Mouse
Conjugation:	Unconjugated
Clone:	5T238
Purification:	Protein A

Applications

Verified Activity:	<p>1. Anti-VCAM1 rabbit monoclonal antibody at 1:500 dilution.</p> <ul style="list-style-type: none">-Lane A: NIH 3T3 Whole Cell Lysate.-Lane B: Mouse brain tissue Lysate.-Lane C: Mouse kidney tissue lysate.-Lysates/proteins at 30 µg per lane.-Secondary-Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. <p>-Developed using the ECL technique.</p> <ul style="list-style-type: none">-Performed under reducing conditions.-Predicted band size:81 kDa.-Observed band size:100 kDa. <p>2. Flow cytometric analysis of Mouse VCAM1(CD106) expression on BABL/c bone marrow cells. Cells were stained with purified anti-Mouse VCAM1(CD106), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.</p>
Application:	FCM,WB
Recommended	WB: 1:500-1:2000; FCM: 1:25-1:100

Properties

Stability & Storage:	Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Mouse VCAM1/VCAM-1/CD106 Protein (TMPY-01830)
Antigen Species:	Mouse
Synonyms:	vascular cell adhesion molecule 1;INCAM-100;VCAM-1;CD106

Research Background

Vascular cell adhesion molecule 1 (VCAM-1), also known as CD106, is a cell surface sialoglycoprotein belonging to the immunoglobulin superfamily. Two forms of VCAM-1 with either six or seven extracellular Ig-like domains are generated by alternative splicing, with the longer form predominant. VCAM-1 is an endothelial ligand for very late antigen-4 (VLA-4) and α 4B7 integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell

A DRUG SCREENING EXPERT

adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential anti-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes. Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481